Next-Generation Antibody Therapeutics Aid Healthcare

NEW YORK - June 30, 2023 - PRLog -- The next-generation antibody therapeutics industry has garnered $5,619.7 million revenue in 2021, and it is projected to generate $15,308.6 million in 2030, rising at a rate of 11.8% from 2021 to 2030. It is led by monoclonal antibody technology advancements resulting in high safety and efficacy.

The surging investments in the healthcare sector to expand the industry size results in high antibody success rates and chronic disease treatment, including cancer, and autoimmune diseases.

The antibody-drug conjugates are developed to combat the rising prevalence of chronic diseases. The rise in government grants results in increasing R&D activities by industry players, which further results in higher revenue generation, after the approval for marketing.

The advancements in ADCs, glycoengineered antibodies, and bispecific antibodies have resulted in antibody therapeutics development with enhanced characteristics.

The oncology category captures the larger industry share, accounting for 80% in 2021, and it is projected to showcase substantial growth, accounting for 13%, in the coming years. It is led by the growing prevalence of prostate cancer, breast cancer, brain cancer, lung cancer, and colorectal cancer, as antibody therapeutics provide advantages throughout the treatment.

The ADC category is projected to generate the largest industry revenue share, advancing at a rate of 12% in the coming years. It is ascribed to the rising demand for antibody-based cancer therapy, with the rising prevalence of breast cancer, and technological advancements. It results in a rising number of conjugates under clinical trials.

Browse detailed report analysis on Next-Generation Antibody Therapeutics Industry Forecast Report 2030 (https://www.prnewswire.com/news-releases/next-generation-...)

The advancements of bispecific antibodies provide lucrative opportunities for the design of novel protein therapeutics. A bispecific antibody helps in utilizing protein engineering techniques for connecting two antigen-binding domains, enabling a single antibody to bind various antigens simultaneously.

Mostly bispecific antibodies are designed for recruiting the cytotoxic effector cells of the immune system for targeting pathogenic cells. Catumaxomab was the first approved bispecific antibody that got approval back in 2009, in Europe.

The major companies operating in the industry are; Amgen Inc., Xencor Inc., Catalent Inc., Pfizer Inc., ImmunoGen Inc., Seagen Inc., Kyowa Kirin Co. Ltd., F.Hoffmann-La Roche Ltd., AstraZeneca plc, and Xencor Inc.